1. Giving a brief hint in the "Introduction" section about GWAS and Radiogenomics (using SNPs and radiographic imaging), specifically for inflammatory rheumatic diseases, will be an added value for the manuscript. Radiogenomics is one of the promising fields which is considered a step towards personalized medicine by providing comprehensively new measured parameters for biomarker discovery.
2. This reviewer doesn't accept providing an abbreviation or acronym (DANBIO) as a keyword. The full name should be provided.
3. Don't use abbreviations before providing the full name and defining them first. For example (REMARK, STROBE, STARD, Da, and DK) . Then, always use the abbreviation. 4. In Abstract: "Observational and translational open cohort study with prospective collection of clinical data and biological materials (primarily blood) in patients with inflammatory rheumatic diseases treated in routine care." This sentence seems to be incomplete. figure 1A was about 20,000, while the total number of the subcategories was (13,500+2,000+3,000+2,700) 21,200.
The number of patients in
6. In Figure 1B , please modify as follows: "Stop of treatment at any time due to adverse events or treatment withdrawal". 7. The sentence "plasma and serum are stored at -80˚C." may be added to Figure 1B. 8. The reference number 36: please specify where was this manuscript submitted? -Anti-drug Ab might be abbreviated ADAb rather than ADA in order to be distinguished from Adalimumab -ADAbs against other biologics than IFX are not assessed?
REVIEWER
-The authors mentioned that this biobank will be further available for national/international collaborations: when this will be possible? This point should be interesting for the readers.
- Figure 1 : numbers should be corrected in order to obtain 20.000
Minor: The manuscript entitled "Identification of new biomarkers to promote personalized treatment of patients with inflammatory rheumatic disease, an open cohort study" has merit, and well presented. In this paper, the authors introduces a protocol for the identification of diagnostic, prognostic, and predictive biomarkers for Danish patients with the inflammatory rheumatic disease to reach precision medicine. The study is considered of interest in its field. The manuscript may be accepted after fulfilling the following minor concerns:
Response: Thank you for a very relevant comment. We are aware that radiogenomics is a promising methodology within cancer and oncology. However, as the method has not been introduced within rheumatology, we have not included it in the present manuscript. In the present study design radiographic imaging is used as part of routine care.
